KOD Options Trading Begins for February 2026 in Its First Week
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Source: NASDAQ.COM
Put Contract Overview: The $20.00 put contract for KOD has a bid of $1.90, allowing investors to buy shares at a cost basis of $18.10, which is a 24% discount from the current price of $26.35. There is a 78% chance the contract may expire worthless, offering a potential 9.50% return on cash commitment.
Call Contract Overview: The $29.00 call contract has a bid of $3.00, and if shares are purchased at $26.35 and the call is sold, it could yield a total return of 21.44% if exercised. There is a 45% chance this contract may also expire worthless, providing an 11.39% additional return.
Volatility Insights: The implied volatility for the put contract is 157%, while the call contract's implied volatility is 136%. The actual trailing twelve-month volatility is calculated at 120%.
YieldBoost Concept: Both the put and call contracts offer potential YieldBoosts, with the put providing a 55.04% annualized return if it expires worthless, and the call offering a 65.96% annualized return under similar conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KOD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KOD
Wall Street analysts forecast KOD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KOD is 27.86 USD with a low forecast of 14.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 25.430
Low
14.00
Averages
27.86
High
50.00
Current: 25.430
Low
14.00
Averages
27.86
High
50.00
About KOD
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BofA Raises Teradyne Price Target to $260 Amid Strong Buy Rating
- Price Target Increase: BofA Securities raised Teradyne's price target from $250 to $260 while maintaining a Buy rating, reflecting confidence in the company's growth potential, with shares closing at $231.89 on Tuesday, indicating market recognition of its prospects.
- Alphabet Rating Upgrade: Raymond James increased Alphabet's price target from $315 to $400 and upgraded the rating from Outperform to Strong Buy, signaling optimism about the recovery of its advertising business, with shares closing at $328.38 on Wednesday, showcasing investor confidence in its future performance.
- Elanco Price Adjustment: Piper Sandler raised Elanco's price target from $24 to $30, upgrading the rating from Neutral to Overweight, reflecting expectations for increased demand for its animal health products, with shares closing at $24.30 on Wednesday, indicating a positive market outlook.
- Teledyne Price Target Boost: Needham increased Teledyne's price target from $615 to $700 while maintaining a Buy rating, demonstrating analyst confidence in its technology and market position, with shares closing at $621.79 on Wednesday, reflecting investor expectations for future growth.
Continue Reading
Kodiak Sciences to Present at J.P. Morgan Conference on January 12, 2026
- Conference Presentation: Kodiak Sciences will present at the J.P. Morgan Healthcare Conference on January 12, 2026, showcasing its latest advancements in retinal disease treatments, which is expected to attract investor and industry attention.
- Clinical Research Progress: The company is advancing three late-stage clinical programs, with Tarcocimab and KSI-501 targeting the $15 billion anti-VEGF market, and topline data readouts expected in Q1 and Q3 2026, potentially impacting market positioning.
- New Drug Development: KSI-101, a bispecific protein, is undergoing two BLA clinical trials for Macular Edema Secondary to Inflammation, with data expected in Q4 2026 and Q2 2027, which could further enrich the product pipeline if successful.
- Market Potential: Kodiak Sciences is committed to developing transformative therapeutics aimed at addressing the leading causes of blindness globally, and with the release of clinical data, the company is poised to capture a larger market share in the biotechnology sector.
Continue Reading